Open Access Open Access  Restricted Access Subscription or Fee Access

Integration of viral hepatitis services into opioid treatment programs

Thomas F. Kresina, PhD, R. Douglas Bruce, MD, MA, MSc, Robert Lubran, MS, H. Westley Clark, MD, JD, FASAM

Abstract


Opioid treatment programs (OTPs) dispense methadone and buprenorphine under specific federal regulations to individuals diagnosed with opioid dependence. OTPs can provide a comprehensive therapeutic milieu, often including primary medical care, psychosocial counseling, vocational rehabilitation, ongoing performance monitoring, and other vital services. Because of the high prevalence of infectious diseases, particularly hepatitis C virus infection, model OTPs are developing comprehensive care and treatment programs that integrate general medical and infectious disease-related medical care with substance abuse and mental health services. Integrating hepatitis care services in the substance abuse treatment settings fosters access to care for patients with multiple comorbidities, many who otherwise would not receive needed care. Improving health related outcomes for this patient population with complex medical problems requires an advanced integrated model of care for OTPs that can be exemplified through establishing resources needed to prevent hepatitis infection as standard of care. Outcomes management becomes possible through enhancing current capability of existing dispensing programs. This may serve as a national model for highly cost-efficient healthcare that has a measurable outcome of improved health.

Keywords


hepatitis, methadone, health services, opioid treatment programs

Full Text:

PDF

References


Brown R: Heroin dependence. Wisconsin Med J. 2004; 103(4): 20-26.

Manchikanti L, Singh A: Therapeutic opioids: A ten year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008; 11(2 Suppl): S63-S88.

Qureshi NA, al-Ghamdy YS, al-Habeeb TA: Drug addiction: A general review of new concepts and future challenges. East Mediterr Health J. 2000; 6(4): 723-733.

Sylvestre DL, Loftis JM, Hauser P et al.: Co-occurring hepatitis C, substance use and psychiatric illness: Treatment issues and developing integrated models of care. J Urban Health. 2004; 81(4): 719-734.

CDC: Hepatitis Surveillance Report No. 59. Atlanta, GA: US Department of Health & Human Services, Centers for Disease Control and Prevention, 2004. Available at www.cdc.gov/hepatitis.

SAMHSA: 2004 National Survey on Drug Use and Health. Rockville MD: DHHS, 2004. Available at http://oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/toc. Accessed November 5, 2008.

ONDCP: Drug Abuse in America [slide presentation]. Washington, DC: Office of National Drug Control Policy, 2002. Available at http://www.whitehousedrugpolicy.gov. Accessed November 5, 2008.

Millson P, Challacombe l, Villeneuve PJ, et al.: Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs. Eur Addict Res. 2006; 12(2): 74-82.

Puigdollers E, Domingo-Salvany A, Brugal MT, et al.: Characteristics of heroin addicts entering methadone maintenance treatment: Quality of life and gender. Subst Use Misuse. 2004; 39(9): 1353-1368.

Millson PE, Challacombe L, Villeneuve PJ, et al.: Self-perceived health among Canadian opiate users: A comparison to the general population and to other chronic disease populations. Can J Public Health. 2004; 95(2): 99-103.

Mizuno Y, Purcell D, Borkowski TM, et al.: The life priorities of HIV-seropositive injection drug users: Findings from a community- based sample. AIDS Behav. 2003; 7(4): 395-403.

Bell J, Zador D: A risk-benefit analysis of methadone maintenance treatment. Drug Saf . 2000; 22(3): 179-190.

Giacomuzzi SM, Ertl M, Kemmler G, et al.: Sublingual buprenorphine and methadone maintenance treatment: A three year follow-up of quality of life assessment. Scientific World J. 2005; 5: 452-468.

Vanagas G, Padaiga Z, Bagdonas E: Cost-utility analysis of methadone maintenance treatment: A methodological approach. Sub Use Misuse. 2006; 41(1): 87-101.

ONDCP: Methadone. Fact Sheet. Washington, DC: Office of National Drug Control Policy, 2000. Available at http://www.whitehousedrugpolicy.gov. Accessed November 5, 2008.

Conway KP, Kane RJ, Ball SA, et al.: Personality, substance of choice, and polysubstance involvement among substance dependent patients. Drug Alcohol Depend. 2003; 71(1): 65-75.

Galanter M, Dermatis H, Glickman I, et al.: Network therapy: Decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat. 2004; 26(4): 313-318.

Gonzales RA, Weiss F: Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998; 18(24): 10663-10671.

Kullig CC, Bereford TP: Hepatitis C in alcohol dependence: Drinking versus disulfiram. J Addict Dis. 2005; 24(2): 77-89.

Wong LL, Limm WM, Tsai N, et al.: Hepatitis B and alcohol affect the survival of hepatocellular carcinoma patients. World Gastroenterol. 2005; 11(23): 3491-3497.

Kresina TF, Hoffman K, Lubran R.: A Pilot Hepatitis Vaccination Program For Substance Abuse Treatment Settings. Abstract presented at the 2005 CDC HCV Prevention Conference. Washington, DC.

SAMHSA: Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) 42. 2005; DHHS Publication No. 05-3993. Rockville, Md. Available at http://www.dpt.samhsa.gov/reports/index.htm. Accessed November 5, 2008.

SAMHSA: National Performance Outcome Measures. 2005. Available at http://www.dpt.samhsa.gov/reports/index.htm and www.smdi.com. Accessed November 5, 2008.

Gowing l, Farrell M, Bornemann R, et al.: Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004; CD004145.

Johnson RE, McCaugh JC: Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep. 2000; 2(6): 519-526.

NIDA: Principles of Drug Addiction Treatment: A Research Based Guide. Washington, DC: US Department of Health & Human Services, 2000. NIH Publication No 00.4180.

SAMHSA: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. A treatment improvement protocol. TIP 40. 2004; Available at http://www.kap.samhsa.gov/products/manuals/index.htm. Accessed November 5, 2008.

SAMHSA: Medication assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) 43. 2005; DHHS Publication No. 05-4048. Rockville Md. Available at http://www.dpt.samhsa.gov/reports/index.htm. Accessed November 5, 2008.

Kresina TF, Maxwell C, Parrino MW, et al.: Testing and Counseling for Hepatitis B, Hepatitis C, and HIV Infections in Opioid Treatment Programs (OTP’s). Summary results from two surveys. Abstract presented at the 2005 CDC HCV Prevention Conference. Washington, DC.

Edlin BR, Kresina TF, Raymond DB, et al.: Care for hepatitis C disease and barriers to care among injection drug users. Clin Infect Dis. 2005; 40: S276-S285.

Backmund M, Meyer K, Henkel C, et al.: Risk factors and predictors of human immunodeficiency virus infection among injection drug users. Eur Addict Res. 2005; 11(3): 138-144.

Kuo I, Sherman SG, Thomas DL, et al.: Hepatitis B virus infection and vaccination among young injection and non-injection drug users: Missed opportunities to prevent infection. Drug Alcohol Depend. 2004; 73(1): 69-78.

Zweben JE. Hepatitis C: Education and counseling issues. J Addict Dis. 2001; 20(1): 33-42.

Fiellin DA, Rosenheck RA, Kosten TR: Coordination of medical care and opioid dependence treatment in primary care: A case report. Substance Abuse. 2003; 24(1): 43-6.

NIH: Consensus Development Conference Statement: Management of Hepatitis C: 2002. Final statement August 26, 2002. Available at http://consensus.nih.gov. Accessed November 5, 2008.

Schaefer M, Heinz A, Backmund M: Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction. 2004; 99(9): 1167-1175.

Novick DM, Kreek MJ: Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008; 103(6); 905-918.

Robaeys G, Buntinx F: Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg. 2005; 68(1): 55-57.

Krook AL, Stokka D, Heger at al.: Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study. Eur Addict Res. 2007; 13(4): 216-221.

Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007; 19(9): 741-747.

Schaefer M, Hinzpeter A, Mohmand A, et al.: Hepatitis C treatment in “difficult-to-treat” psychiatric patients with peglated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology. 2007; 46(4): 991-998.

Belfiori B, Chiodera A, Cilegi P, et al.: Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: A prospective multicentre study. Eur J Gastroenterol Hepatol. 2007; 19(8): 731-732.

Semba RD, Ricketts EP, Mehta SF, et al.: Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore. Am J Drug Alcohol Abuse. 2007; 33(1): 71-80.

Robaeys G, Van Vlierberghe H, Mathei C, et al.: Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006; 18(2): 159-166.

Gupta SK, Sellers E, Somoza E, et al.: The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in paitnets with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharm. 2007; 47(5): 604-612.

Berk SI, Litwin AH, Arnsten JH, et al.: Effects of peglyated interferon alfa-2b on the pharmacokinetic and pharmacodynamics properties of methadone: A prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther. 2007; 29(1): 131-138.

Sulkowski M, Wright T, Rossi S, et al.: Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis c undergoing methadone maintenance therapy. Clin Pharmacol Ther. 2005; 77(3): 214-224.

Edlin BR, Seal KH, Lorvick J, et al.: Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001; 345(3): 211-214.

Dore GJ, Thomas DL: Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Sem Liver Dis. 2005; 25(1): 18-32.

Botero RC: Should patients with chronic hepatitis C infection be transplanted? Transplant Proc. 2004; 36(5): 1449-1454.

Mandayam S, Jamal MM, Morgan TR: Epidemiology of alcoholic liver disease. Semin Liver Dis. 2004; 24(3): 217-232.

Hser Y-I, Evans E, Huang D, et al.: Relationship between drug treatment services, retention, and outcomes. Psychiat Serv. 2004; 55(7): 767-774.

Booth RE, Corsi KF, Mikulich-Gilbertson SK: Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004; 74(2): 177-185.

CDC: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998; 47 (RR-19): 1-33.

Davis GL, Rodrigue JR: Treatment of chronic hepatitis C in active drug users. N Engl J Med. 2001; 345(3): 215-217.

Inglesby TV, Rai R, Astemborski J: A prospective, communitybased evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999; 29(2): 590-596.

McCarthy JJ, Flynn N: Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. J Addictive Dis. 2001; 20(1): 19-31.

NIDA: Hepatitis C. NIDA Community Drug Alert Bulletin. Washington, DC: US Department of Health & Human Services, 2000. NIH Publication No. 00-4663.

Stein MD, Maksad J, Clarke J: Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Dep. 2001; 61(3): 211-215.

Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8): 556-562.

Aitken CK, Kerger M, Crofts N: Peer-delivered hepatitis C testing and counseling: A means of improving the health of injection drug users. Drug Alcohol Rev. 2002; 21(1): 33-37.

Sylvestre DL: Treating hepatitis C in methadone maintenance patients: An interval analysis. Drug Alcohol Dep. 2002; 67(2): 117-123.

Sylvestre DL, Litwin AH, Clements BJ, et al.: The impact of barriers to HCV treatment in recovering heroin users maintained on methadone. J Sub Abuse Treat. 2005; 29(3): 159-165.

Bruce RD, Acosta A, Lim J, et al.: Initial lessons in hepatitis C treatment in methadone maintenance: Directly observed therapy vs. standard-of-care. College on Problems of Drug Dependence. San Juan Puerto Rico, June 14-19, 2008, poster #90.

Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management and treatment of hepatitis C. AASLD Practice Guideline. Hepatology. 2004; 39(4): 1147-1171.

Alter MJ, Seeff LB, Bacon B, et al.: Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Int Med. 2004; 141(9): 715-719.

Tramarin A, Gennaro N, Compostella FA, et al.: HCV screening to enable early treatment of hepatitis C: A mathematical model to analyze costs and outcomes in two populations. Curr Pharm Des. 2008; 14(17); 1655-1660.

Weigand J, Deterding K, Cornberg M, et al.: Treatment of acute hepatitis C: The success of monotherapy with (peglyated) interferon ά. J Antimicrob Chemother. 2008; doi:10.1093/jac/dnk346.

Santantonio T, Fasano M: Therapy of acute hepatitis C: A review of literature. Curr Pharm Des. 2008; 14(17): 1686-1689.

Fabris P, Fleming VM, Giordani MT, et al.: Acute hepatitis C: Clinical aspects, diagnosis, and outcome of acute HCV infection. Curr Pharm Des. 2008; 14(17): 1681-1685.

Villano SA, Vlahov D, Nelson KE, et al.: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999; 29(3): 908-914.

Leavitt SB: Liver disease in MMT: Treatment and transplant. Part 1: Critical concerns. Addict Treatment Forum. 2001; 10(4). Available at http://www.atforum.com. Accessed November 5, 2008.

Chitturi S, George J: Predictors of liver-related complications in patients with chronic hepatitis C [editorial]. Ann Med. 2000; 32(9): 588-591.

Wong LL, Tsai N, Limm W, et al: Liver transplant for hepatocellular cancer: A treatment for select few. Clin Transplant. 2004; 18(2): 205-210.

Astone J, Strauss SM, Vassilev ZP, et al.: Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ. 2003; 33(1): 107-117.

Strauss SM, Astone J, Vassilev ZP, et al.: Gaps in the drugfree and methadone maintenance treatment program response to hepatitis C. J Subst Abuse Treat. 2003; 24(4): 291-297.

Strauss SM, Astone JM, Hagan H, et al.: The content and comprehensiveness of hepatitis C education in methadone maintenance and drug free treatment units. J Urban Health. 2004; 81(1): 38-47.

Astone JM, Strauss SM, Hagan H, et al.: Outpatient drug treatment program director’s hepatitis C-related beliefs and their relationship to the provision of HCV services. Am J Drug Alcohol Abuse. 2004; 30(4): 783-797.

Hagan H, Strauss SM, Astone JM, et al.: Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis. 2005; 40(suppl 5): S297-S303.

Munoz-Plaza CE, Strauss SM, Astone-Twerwll JM, et al.: Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs. J Psychoactive Drugs. 2006; 38(3): 233-241.

Walley AY, White MC, Kushel MB, et al.: Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Sub Abuse Treat. 2005; 28(2): 181-187.

Weaver MF, Cropsey KL, Fox SA: HCV prevalence in methadone maintenance: Self report versus serum test. Am J Health Behav. 2005; 29(5): 387-394.

Schackman BR, Tiexeira PA, Beeder AB: Offers of hepatitis C care do not lead to treatment. J Urban Health. 2007; 84(3): 455-458.

Cox J, De P, Morissette C, et al.: Low perceived benefits and self-efficacy are associated with hepatitis C virus (HCV) infectionrelated risk among injection drug users. Soc Sci Med. 2008; 66(2): 211-220.

Tucker T, Fry CL, Lintzeris N, et al.: Randomized controlled trial of a brief behavioral intervention for reducing hepatitis C virus risk practices among injection drug users. Addiction. 2004; 99(9): 1157-1166.

Evans M, Hokanson PS, Augsburger J, et al.: Increasing knowledge and HIV and hepatitis C during substance abuse treatment. Addict Dis Treat. 2005; 4(1): 71-76.

Walley AY, White MC, Kushel MB, et al.: Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Sub Abuse Treat. 2005; 28(2): 181-187.

Schafer M: Psychiatric patients, methadone patients, and earlier drug users can be treated for HCV when given adequate support services. Presentation at Digestive Disease Week; May 20-23, 2001, Atlanta, GA.

Blechman MB, Charney JA, Friedman P, et al.: Interferonalfa (IFN-α) therapy in patients with chronic hepatitis C (CHC) on methadone. Hepatology. 1999; 30: 482A. Abstract 1287.

Hagan H, Haynes H, Willson RA, et al.: Feasibility of alphainterferon administration to opiate addicts in a methadone treatment setting. Hepatology. 1999; 30(4 Part 2): 624A.

Sylvestre DL, Zweben JE: Integrating HCV services fro drug users: A model to improve engagement and outcomes. Int J Drug Policy. 2007; 18(5): 406-410.

Zeller N, Gillani FS, Rich JD: A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care 2007; 19(9): 1128-1133.

Taylor L: Delivering care to infection drug users coinfected with HIV and Hepatitis C virus. Clin Inf Dis. 2005; 40: S255-S261.

Strauss S, Astone JM, Des Jarlais D, et al.: Integrating hepatitis C services into existing HIV services: The Experiences of a sample of US drug treatment units. AIDS Patient Care STD. 2005; 19(2): 78-88.

Litwin AH, Soloway I, Gourevitch MN: Integrating hepatitis C services with methadone maintenance. Clin Infect Dis. 2005; 40(suppl 5): S339-S345.

Bonkowsky HL, Tice AD, Yapp RG, et al.: Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of directly observed therapy and self administration. Am J Gastroenterol. 2008; 103(1): 1-9.

Gunn RA, Lee MA, Callahan DB, et al.: Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med. 2005; 29(1): 27-33.

Kresina TF, Bruce D, Cargill V, Cheever LW: Integrating HCV Care and HIV Primary Care for the Injection Drug User Coinfected with HIV and HCV. Clin Inf Dis. 2005; 41(Suppl 1): S-83-8.

AASLD: Diagnosis, Management and Treatment of Hepatitis C, AASLD Practice Guideline. Hepatology. 2004; 39: 1147-1171.

Fletcher BW, Broome KM, Delany PJ, et al.: Patient and program factors in obtaining supportive services in DATOS. J Subst Abuse Treat. 2003; 25(3): 165-175.

Novick DM: The impact of hepatitis C virus infection on methadone maintenance treatment. Mt Sinai J Med. 2000; 67(5/6): 437-443.

Sweeney LP, Samet JH, Larson MJ, Saitz R: Establishment of a multidisciplinary health evaluation and linkage to primary care (HELP) clinic in a detoxification unit. J Addict Dis. 2004; 23(1): 33-45.

Rowan-Szal GA, Chatham LR, Joe GW, Simpson DD: Services provided during methadone treatment. A gender comparison. J Subst Abuse Treat. 2000; 19(1): 7-14.




DOI: https://doi.org/10.5055/jom.2008.0041

Refbacks

  • There are currently no refbacks.